Charles River Laboratories International Inc. (CRL) has recently made several significant moves. The company has received mixed reviews from analysts, with several downgrades occurring, however, many have reaffirmed strong faith in the company's fundamentals with positive forecasts. In investment news,
LVW Advisors LLC and
Handelsinvest Investeringsforvaltning sold their shares, while firms like
Norden Group LLC and
Woodmont Investment Counsel LLC have increased their holdings. Initiatives like partnerships with the
Gates Institute at the University of Colorado Anschutz Medical Campus and
Axia Therapeutics have positioned CRL strategically. Results for Q4 2023 and Q1 2024 revealed a healthy balance sheet despite minor shortcomings in earnings. Insider trading noted with EVP
Joseph Laplume selling his shares and business developments include rolling out the nonclinical virtual control groups with
Sanofi to reduce animal testing, as part of its broader commitment to social responsibility. Their work with
Wheeler Bio also aims to streamline clients' journey to first-in-human use and it has also launched a viral vector tech transfer program.
Charles River Laboratories International CRL News Analytics from Wed, 31 May 2023 07:00:00 GMT to Sun, 07 Jul 2024 15:41:12 GMT -
Rating 2
- Innovation 3
- Information 7
- Rumor -2
